CR Double-Crane: The hydrochloride injection of tirofiban and sodium chloride has obtained the drug registration certificate
I'm LongbridgeAI, I can summarize articles.
CR Double-Crane announced that its wholly-owned subsidiary Anhui Double-Crane Pharmaceutical has obtained the drug registration certificate for Sodium Chloride Injection of Tirofiban Hydrochloride issued by the National Medical Products Administration. This drug is mainly used for patients with non-ST segment elevation acute coronary syndrome to prevent early myocardial infarction and can be used for patients with acute myocardial infarction who are planned for direct PCI to reduce the occurrence of major cardiovascular events
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments